Picture loading failed.

Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-337-1mg 1mg 3090
GMP-Bios-ab-337-10mg 10mg Inquiry
GMP-Bios-ab-337-100mg 100mg Inquiry
GMP-Bios-ab-337-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Matuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody
INN Name Matuzumab
TargetEGFR
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCnd
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure3c08:HL/5vr9:HL:AB
99% SI Structure5vsi:HL/3c09:HL:CB
95-98% SI StructureNone
Year Proposed2003
Year Recommended2003
CompaniesImClone Systems;Merck KGaA;Takeda
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer
Development Techna